Sophie J. Beale

North Yorkshire, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Digital front door technologies to pre-assess people before assessment for NHS Talking Therapies [HTE10055]: early value assessment.

Digital front door technologies to pre-assess people before assessment for NHS Talking Therapies [HTE10055]: early value assessment.

Journal: Health technology assessment (Winchester, England)

Published: June 29, 2026

Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis.

Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis.

Journal: Health technology assessment (Winchester, England)

Published: September 10, 2024

Correction: Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15.

Correction: Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15.

Journal: PharmacoEconomics - open

Published: December 05, 2023

Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation.

Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation.

Journal: Health technology assessment (Winchester, England)

Published: October 15, 2023

Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15.

Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15.

Journal: PharmacoEconomics - open

Published: September 03, 2023

Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Journal: PharmacoEconomics - open

Published: March 08, 2023

Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Journal: PharmacoEconomics - open

Published: February 27, 2023

A systematic review of cost-utility analyses of screening methods in latent tuberculosis infection in high-risk populations.

A systematic review of cost-utility analyses of screening methods in latent tuberculosis infection in high-risk populations.

Journal: BMC pulmonary medicine

Published: April 28, 2022

Prophylactic removal of impacted mandibular third molars: a systematic review and economic evaluation.

Prophylactic removal of impacted mandibular third molars: a systematic review and economic evaluation.

Journal: Health technology assessment (Winchester, England)

Published: June 27, 2020

Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Journal: PharmacoEconomics - open

Published: April 16, 2020

Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Journal: PharmacoEconomics - open

Published: March 25, 2020

Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.

Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.

Journal: Health technology assessment (Winchester, England)

Published: January 15, 2020

Showing 1-12 of 33

Last Updated: 09/26/2026